|
BioNTech
melanoma fixvac vaccine in combination with anti-pd1 therapy ![]() Melanoma Fixvac Vaccine In Combination With Anti Pd1 Therapy, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+pd+1+combination+treatment/melanoma+fixvac+vaccine+in+combination+with+anti+pd1+therapy/pmc11625737-72-28-65 Average 90 stars, based on 1 article reviews
melanoma fixvac vaccine in combination with anti-pd1 therapy - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Merck & Co
anti-pd-1 ![]() Anti Pd 1, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+pd+1+combination+treatment/pembrolizumab+anti/pmc08699256-209-51-54 Average 90 stars, based on 1 article reviews
anti-pd-1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Bristol Myers
combination therapy (an anti-pd1 and an antiectla-4) ![]() Combination Therapy (An Anti Pd1 And An Antiectla 4), supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+pd+1+combination+treatment/combination+therapy++an+anti+pd1+and+an+antiectla+4+/pm34154881-14-25-4 Average 90 stars, based on 1 article reviews
combination therapy (an anti-pd1 and an antiectla-4) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Bristol Myers
combination therapy with antiil-8 antibodies and anti-pd-1 antibodies ![]() Combination Therapy With Antiil 8 Antibodies And Anti Pd 1 Antibodies, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+pd+1+combination+treatment/combination+therapy+with+antiil+8+antibodies+and+anti+pd+1+antibodies/10__1200_slash_jco__19__00739-174-21-1 Average 90 stars, based on 1 article reviews
combination therapy with antiil-8 antibodies and anti-pd-1 antibodies - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Bochem Instrumente
anti-pd-1 treatment ![]() Anti Pd 1 Treatment, supplied by Bochem Instrumente, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+pd+1+combination+treatment/anti+pd+1+treatment/pm30006738-87-28-34 Average 90 stars, based on 1 article reviews
anti-pd-1 treatment - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Frontiers in Immunology
Article Title: Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy
doi: 10.3389/fimmu.2024.1448489
Figure Lengend Snippet: mRNA vaccine for different cancer types.
Article Snippet: NCT02410733 , Advanced melanoma, specifically stage IIIB-C and stage IV , Tetravalent RNA-lipoplex cancer vaccine , MAGE-A3, NY-ESO-1, tyrosinase, and TPTE , Melanoma FixVac vaccine in combination with
Techniques: Injection, Control, Wilms Tumor Assay, Next-Generation Sequencing, In Situ, Transplantation Assay, Retroviral, Transfection, Ex Vivo, Recombinant
Journal: Cancers
Article Title: Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
doi: 10.3390/cancers13246317
Figure Lengend Snippet: The role of CXCL9/CXCL10 in cancer diseases CXCL9/CXCL10 affect cancer diseases by either: inducing IFNγ high CD4 + Th1 cells ( A ), cytotoxic CD8 + T cells ( B ), inducing growth factors via CXCR3 + epithelial cells ( C ), direct suppression of tumor growth ( D ), The attraction of CXCR3 + T cells and NK cells to the tumor site ( E ) and co-signaling with anti-PD-1 (only CXCL9) ( F ).
Article Snippet: Currently, there are two small chemical class II antagonists produced by Astra-Zeneca that block T regs recruitment (AZD-2098, Marketed, and AZD-1678 in preclinical studies), a small chemical class II antagonist that blocks the interaction between CCL22 and CCR4 (FLX-475 produced by FLx-Bio) in phase 1/2 clinical trials as monotherapy or in
Techniques: